MDLN earnings release — EPS beat +55.2%Medline Inc. (MDLN) 财报发布 — EPS 高于预期+55.2%
Key Results
Actual vs Consensus
Profitability and Cash Flow
Forward Guidance
FY2026 organic-sales growth raised to 9.0–10.0% (previously 8.5–9.5%); adjusted EBITDA cut to $3.3–3.4B (previously $3.5–3.6B), mainly on inflation, operating investment, quality remediation and retail-channel softness.
Official release: Reports Second Quarter and First Six Months 2026 Results
核心结果
实际值与市场预期
财务指标
前瞻指引
2026 年有机销售增长指引上调至 9.0%–10.0%(此前为 8.5%–9.5%);调整后 EBITDA 指引下调至 33–34 亿美元(此前为 35–36 亿美元),主要受通胀压力、运营投入、质量整改和零售渠道疲软影响。
For information only. Not investment advice.内容仅供参考,不构成投资建议。